Intellectual property rights, especially patents, frequently form the foundation of value in a life sciences company. If conducted with eventual commercial success in mind, a due diligence review of an IP portfolio can enable an investor to assess more accurately the present and future value of the technology and IP associated with an investment. Often times however, little thought is given as to how to leverage the harvested intelligence in the commercialization process of the acquired technology after the deal. This panel discussed:
- The IP due diligence process – what to expect and preparing for the unexpected
- Working the IP – identifying and valuing know-how to execute the IP
- The technology factor – working with R & D during and after the diligence process
Related Insights
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.
June 4, 2025
Energy Current
Nuclear’s Comeback: What Renewables Professionals Should Know
The clean energy transition isn’t a zero-sum game – it’s a team effort. And one player is stepping back into the spotlight with renewed…
June 4, 2025
Foley Ignite
M&A Disputes Set to Rise in Latin America: How Savvy Investors Are Protecting Themselves
As deal activity shows signs of rebounding in 2025, investors are bracing for an increase in M&A-related disputes globally, and Latin…